Quantcast
Free Trial!
Today’s Best Stocks To Trade!  Click Here


 

Research and Markets: IMS World Review Country Profile - Germany - All Data Is Available Over a 5 Year Period for Easy Trend Analysis And Is Based On Quarter 4 Sales Figures

Wed. April 23, 2008; Posted: 08:51 AM
Stocks RSS
Dublin, Apr 21, 2008 (M2 PRESSWIRE via COMTEX) -- RX | news | PowerRating | PR Charts -- Research and Markets (http://www.researchandmarkets.com/reports/c89469) has announced the addition of IMS World Review Country Profile - Germany to their offering

IMS Health's Country Profiles provide a comprehensive insight into the national sales of the pharmaceutical market in selected countries over 5 years. Each individual IMS Company Profile analyzes the critical components that make up a pharmaceutical company, providing you with a clear assessment of the relative strengths and weaknesses of a company's business strategy. Sales performance is analysed in terms of geographic region, major corporations, therapeutic classes, major products and new product activity.

All data is available over a 5 year period for easy trend analysis and is based on Quarter 4 sales figures.

Products Mentioned:

- Accuchek Comfort

- Betaferon

- Enbrel

- Glivec

- Nexium

- Pantozol

- Plavix

- Rebif

- Symbicort

- Viani

Content Outline:

PREFACE

IMS World Review Country Profile: Germany (Sell- in)

Data Values and Definitions

Channels of Distribution

Audited Market Trend

Leading Companies - Top 35

Leading Corporations - Top 35

Fastest Growing Companies

Market Share By Corporate Nationality

15 Largest Therapeutic Classes

15 Fastest - Growing 3rd And 4th Level Therapeutic Classes

Therapeutic Class Profile

Leading Products - Top 40

Leading New Products - Top 40

Forms Most Commonly Used - Top 15

APPENDIX

Anatomical Therapeutic Classification

Companies Mentioned:

- Abbott

- Altana

- Amgen

- Astellas

- Astrazeneca

- Bayer

- Berlin- Ch/Menarini

- Betapharm

- Boehringer I.

- Bristol- M.- Squibb

- Emra- Med

- Essex Pharma

- Eurim- Pharm

- Fresenius Kabi

- Gruenenthal

- Gsk

- Hexal

- Janssen- Cilag

- Kohlpharma

- Lilly

- Msd

- Mundipharma

- Novartis Pharma

- Novo Nordisk

- Pfizer Pharma

- Ratiopharm

- Roche Diagnostics

- Roche Pharma

- Sanofi- Aventis

- Schering

- Schwarz Pharma

- Serono

- Stada

- Takeda Pharma

- Wyeth Pharma

For more information visit http://www.researchandmarkets.com/reports/c89469

CONTACT: Laura Wood, Senior Manager, Research and Markets Fax: +353 1 4100 980 e- mail: press@researchandmarkets.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

For full details on Ims Health Inc (RX) click here. Ims Health Inc (RX) has Short Term PowerRatings of 7. Details on Ims Health Inc (RX) Short Term PowerRatings is available at This Link.

    


More News:   Market Updates | Stock Alerts | All Trading News | Stock Index

Email
Print
Archives
Feedback
Email Article Link
Close X
Recipients email address
Your name
Your email
Add a note (optional)




Stocks RSS





Related News [RX]
PREMIER SPONSORED LINKS
TRADE CENTER
 
The TradingMarkets Directory
RELATED SITES
Nothing but forex
Please call 1-213-955-5858 ext. 1

About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback


All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

© 2008 The Connors Group, Inc.